Disruption of AP3B1 by a chromosome 5 inversion: a new disease mechanism in Hermansky-Pudlak syndrome type 2

BMC Medical Genetics

Andrew D Mumford⁴  Subarna Chakravorty⁶  Josu de la Fuente²  Vandana Bharadwaj²  Kimberly C Gilmour⁷  Richard A Manning⁵  Viv Maloney³  Claire Brooks¹  Sherina L Murden⁴  Matthew L Jones⁴ 

[1] North West Thames Regional Genetics Service, Northwick Park Hospital, Harrow, UK;Department of Medicine, Imperial College, London, UK;Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK;Bristol Heart Institute & School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK;Department of Haematology, Imperial College Academic Health Care Trust, Hammersmith Hospital, London, UK;Department of Paediatric Haematology, St Marys Hospital, Imperial College Healthcare NHS Trust, London, UK;Department of Immunology, Great Ormond Street Hospital for Children NHS Trust, London, UK

关键词: Fluorescence in situ hybridisation;    Adaptor-related protein complex 3 β3A subunit;    Hermansky-Pudlak syndrome type 2;    Chromosome 5 inversion;   

Others  :  1177711
DOI  :  10.1186/1471-2350-14-42

 received in 2012-10-29, accepted in 2013-03-20,  发布年份 2013

【 摘 要 】

Background

Hermansky-Pudlak syndrome 2 (HPS2; OMIM #608233) is a rare, autosomal recessive disorder caused by loss-of-function genetic variations affecting AP3B1, which encodes the β3A subunit of the adaptor-related protein complex 3 (AP3). Phenotypic characteristics include reduced pigmentation, absent platelet dense granule secretion, neutropenia and reduced cytotoxic T lymphocyte (CTL) and natural killer (NK) cell function. To date HPS2 has been associated with non-synonymous, stop-gain or deletion-insertion nucleotide variations within the coding region of AP3B1.

Case presentation

We describe a consanguineous female infant with reduced pigmentation, neutropenia and recurrent infections. Platelets displayed reduced aggregation and absent ATP secretion in response to collagen and ADP, indicating a platelet dense granule defect. There was increased basal surface expression of CD107a (lysosome-associated membrane protein 1(LAMP-1)) on NK cells and CTLs from the study subject and a smaller increase in the percentage of CD107a positive cells after stimulation compared to most healthy controls. Immunoblotting of protein extracts from EBV-transformed lymphoblasts from the index case showed absent expression of full-length AP-3 β3A subunit protein, confirming a phenotypic diagnosis of HPS2.

The index case displayed a homozygous pericentric inv(5)(p15.1q14.1), which was also detected as a heterozygous defect in both parents of the index case. No loss of genetic material was demonstrated by microarray comparative genome hybridisation at 60kb resolution. Fluorescence in-situ hybridisation using the 189.6kb probe RP11-422I12, which maps to 5q14.1, demonstrated dual hybridisation to both 5q14.1 and 5p15.1 regions of the inverted Chr5. The RP11-422I12 probe maps from intron 1 to intron 16 of AP3B1, thus localising the 5q inversion breakpoint to within AP3B1. The probe RP11-211K15, which corresponds to an intergenic region on 5p also showed dual hybridisation, enabling localisation of the 5p inversion breakpoint.

Conclusion

This case report extends the phenotypic description of the very rare disorder HPS2. Our demonstration of a homozygous Chr5 inversion predicted to disrupt AP3B1 gene provides a novel pathogenic mechanism for this disorder.

【 授权许可】

   
2013 Jones et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wei ML: Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res 2006, 19(1):19-42.
• [2]Wei AH, Li W: Hermansky-Pudlak syndrome: pigmentary and non-pigmentary defects and their pathogenesis. Pigment Cell Melanoma Res 2012, 26:176-192.
• [3]Raposo G, Marks MS, Cutler DF: Lysosome-related organelles: driving post-Golgi compartments into specialisation. Curr Opin Cell Biol 2007, 19(4):394-401.
• [4]Badolato R, Parolini S: Novel insights from adaptor protein 3 complex deficiency. J Allergy Clin Immunol 2007, 120(4):735-741. quiz 742–733
• [5]Chiang PW, Oiso N, Gautam R, Suzuki T, Swank RT, Spritz RA: The Hermansky-Pudlak syndrome 1 (HPS1) and HPS4 proteins are components of two complexes, BLOC-3 and BLOC-4, involved in the biogenesis of lysosome-related organelles. J Biol Chem 2003, 278(22):20332-20337.
• [6]Clark R, Griffiths GM: Lytic granules, secretory lysosomes and disease. Curr Opin Immunol 2003, 15(5):516-521.
• [7]Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, Kontny U, Muller C, Nurden A, Rohr J: Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006, 108(1):81-87.
• [8]Fontana S, Parolini S, Vermi W, Booth S, Gallo F, Donini M, Benassi M, Gentili F, Ferrari D, Notarangelo LD: Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood 2006, 107(12):4857-4864.
• [9]Huizing M, Scher CD, Strovel E, Fitzpatrick DL, Hartnell LM, Anikster Y, Gahl WA: Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr Res 2002, 51(2):150-158.
• [10]Jung J, Bohn G, Allroth A, Boztug K, Brandes G, Sandrock I, Schaffer AA, Rathinam C, Kollner I, Beger C: Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood 2006, 108(1):362-369.
• [11]Shotelersuk V, Dell’Angelica EC, Hartnell L, Bonifacino JS, Gahl WA: A new variant of Hermansky-Pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am J Med 2000, 108(5):423-427.
• [12]Wenham M, Grieve S, Cummins M, Jones ML, Booth S, Kilner R, Ancliff PJ, Griffiths GM, Mumford AD: Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. Haematologica 2010, 95(2):333-337.
• [13]Kurnik K, Bartsch I, Maul-Pavicic A, Ehl S, Sandrock-Lang K, Bidlingmaier C, Rombach N, Busse A, Belohradsky BH, Muller-Hocker J: Novel mutation in Hermansky-Pudlak syndrome type 2 with mild immunological phenotype. Platelets 2012.
• [14]Wheeler RD, Cale CM, Cetica V, Arico M, Gilmour KC: A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol 2010, 150(6):727-730.
• [15]Cetica V, Santoro A, Gilmour KC, Sieni E, Beutel K, Pende D, Marcenaro S, Koch F, Grieve S, Wheeler R: STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. J Med Genet 2010, 47(9):595-600.
• [16]Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB: Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol 2011, 163(3):271-283.
• [17]Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmberg K, Langler A, Gross-Wieltsch U, Bay A, Kaya Z: Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood 2011, 118(17):4620-4629.
• [18]Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le Deist F: Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000, 25(2):173-176.
• [19]Shotelersuk V, Hazelwood S, Larson D, Iwata F, Kaiser-Kupfer MI, Kuehl E, Bernardini I, Gahl WA: Three new mutations in a gene causing Hermansky-Pudlak syndrome: clinical correlations. Mol Genet Metab 1998, 64(2):99-107.
• [20]Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, Bossi G, Hamblin T, Davies EG, Griffiths GM: Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 2003, 4(11):1111-1120.
• [21]Chiang PW, Spector E, Thomas M, Frei-Jones M: Novel mutation causing Hermansky-Pudlak Syndrome Type 2. Pediatr Blood Cancer 2010, 55(7):1438.